Clinical Research Directory

Inclusion Criteria: * Age 18 years or older at study regimen initiation. * Metastatic colorectal cancer documented in the oncology electronic health record. * Initiation of trifluridine-tipiracil (FTD-TPI) plus bevacizumab or FTD-TPI alone after two prior systemic treatment regimens for metastatic disease (third-line setting). * Known RAS mutation status at or before study regimen initiation. * Prior treatments included a fluoropyrimidine, irinotecan, and oxaliplatin. Prior anti-VEGF therapy was required for RAS-mutant disease; prior anti-VEGF or anti-EGFR therapy was required for RAS wild-type disease. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 when ascertainable in the electronic health record. Exclusion Criteria: * Anticancer treatment in the four weeks before study regimen initiation. * Another primary malignancy in the five years before or on study regimen initiation, except adequately treated cervical carcinoma in situ or basal cell skin cancer. * Prior FTD-TPI use. * Other anticancer treatment during the treatment assessment window.